Traders should monitor future revenue guidance and test volume metrics in upcoming earnings; this approval positions Myriad for increased market penetration and potential pricing leverage. Consider long-term upside given exclusivity and alignment with standard-of-care treatment.
Price Chart
Executive Summary
Myriad Genetics announced FDA approval of its MyChoice® CDx Test as the companion diagnostic for GSK's Zejula (niraparib) in advanced ovarian cancer patients, based on the PRIMA trial data. This makes MyChoice CDx the only FDA-approved test in the U.S. to identify HRD-positive patients eligible for Zejula, reinforcing Myriad's leadership in ovarian cancer diagnostics and expanding the commercial utility of its test.
Key Facts
- FDA approved Myriad's MyChoice® CDx Test as the companion diagnostic for GSK's Zejula in advanced ovarian cancer.
- The approval is based on final data from the PRIMA trial, using HRD status to stratify patients.
- MyChoice CDx is now the only FDA-approved HRD test in the U.S. for PARP inhibitor eligibility with Zejula.
- The test identifies HRD status via comprehensive BRCA1/2 analysis and genomic instability score (GIS).
- Nearly 50% of advanced ovarian cancer patients have HRD-positive tumors, making this a significant patient population.
Financial Impact
Significant commercial upside potential — test now required for Zejula eligibility, likely increasing adoption and revenue. No direct dollar figure provided, but expands addressable market and strengthens pricing power.
Risk Factors
- Adoption dependent on physician uptake and payer reimbursement.
- Competition from lab-developed tests (LDTs) or future rival CDx approvals.
- Zejula's own market performance and safety profile could impact test utilization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257649 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.86 $4.01 | ▲ +3.89% | ▲ +1.32% | $4.54 (+17.62%) |
Sep 16, 2026 16d ago | Press Release | $3.86 $4.01 | ▲ +3.89% | ▲ +1.32% | $4.54 (+17.62%) |
Aug 4, 2026 8w ago | Press Release | $3.17 $3.22 | ▼ −1.58% | ▼ −1.68% | $4.54 (−43.22%) |
Jul 30, 2026 9w ago | Press Release | $2.86 $3.26 | ▼ −13.99% | ▼ −10.47% | $4.54 (−58.74%) |
May 27, 2026 18w ago | Press Release | $3.93 $4.31 | ▲ +9.67% | ▲ +8.46% | $4.54 (+15.52%) |
Mar 17, 2026 28w ago | Press Release | $4.64 $4.68 | ▲ +0.86% | ▲ +1.58% | $4.54 (−2.16%) |
Feb 28, 2026 30w ago | Institutional Cluster | $5.01 $4.81 | ▼ −3.99% | ▼ −2.78% | $4.54 (−9.38%) |
Feb 24, 2026 31w ago | S-3 | $4.78 $5.28 | ▲ +10.46% | ▲ +11.56% | $4.54 (−5.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access